Cumberland Pharmaceuticals receives FDA waiver, $1.2M refund for RediTrex fees

CUMBERLAND PHARMACEUTICALS INC

FDA granted barrier-to-innovation waiver based on ifetroban clinical programs addressing unmet medical needs.
Company will receive refund of approximately $1.2 million in prescription drug program fees for RediTrex.
Refund expected within 45 days from FDA's Office of Financial Management.
Waiver follows Cumberland's April 3, 2023 request for reconsideration through counsel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.